RT @doctorRBC: Upadacitinib effective in treatment of ankylosing spondylitis pts refractory to biologic tx - phase 3 tri
Tweet Content
Upadacitinib effective in treatment of ankylosing spondylitis pts refractory to biologic tx - phase 3 trial
Primary endpoint (ASAS40) and secondary endpoints met
No malignancy, MACE, VTE, death
@RheumNow #EULAR2022 ABST#POS0306 https://t.co/UL4hUJ0rQV
Show on Archive Page
On
Display in Search Results
On
PDQ
Off